MHRA / UK

Great Britain's Post-Market Surveillance Rules: What Changed in 2025

By Kieran Redington, Founder of MedFortis Published 30 October 2026 ~7 min read

While the EU is discussing lighter post-market reporting, Great Britain has gone the other way. Since 16 June 2025, devices placed on the market in Great Britain have been covered by new post-market surveillance rules that set shorter deadlines and give the MHRA quicker access to your reports. Over a year in, many teams are still working out what it means day to day.

What the new rules are

The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 added a new Part 4A to the UK Medical Devices Regulations 2002. It applies to medical devices, including IVDs and active implantables, placed on the market or put into service in Great Britain from 16 June 2025. The MHRA published guidance alongside it, and a table of the main changes, which is the best short summary.

Northern Ireland follows EU rules, so this guide is about Great Britain only.

The changes that matter most

A written PMS plan is now a legal requirement

Every manufacturer needs a post-market surveillance plan, and the MHRA expects the feedback it describes to include patient and public input, not only complaints and sales data.

Shorter deadlines for some incidents

Where a serious deterioration in health is anticipated, the incident must be reported within 15 days. It used to be 30. A use error is reportable if it could lead to a serious deterioration in health, even if none has happened yet. Incident reports must include the device's UDI where there is one.

Trend reporting is wider

Trend reports now cover incidents that are reportable on their own as well as those that aren't, and the rules set out what a trend report must contain.

Reports on a fixed footing

The PMS report must be updated at least every three years. PSURs follow a standard format, are updated at set intervals, go to your UK approved body, and are reviewed for any impact on your certificate. Check the MHRA guidance for the interval that applies to your device's class.

Corrective actions shared more widely

Manufacturers must tell their UK responsible person, and their approved body if they have one, about every preventive and corrective action taken to deal with a risk or a non-conformity affecting safety or performance.

Field safety notices and actions abroad

Before a field safety notice goes to customers, the proposed notice must now be sent to the MHRA, and the rules set out when it can then be distributed. The notice must include UDI information where available and be in a searchable format.

One change is easy to overlook. If you take a field safety corrective action outside Great Britain, and the same type of device is supplied in Great Britain but isn't affected, you still have to tell the MHRA. That means your UK team needs to know about corrective actions everywhere you sell, not only in the UK.

Three working days

Several parts of the new rules give the MHRA a quick route to your information. You have three working days to provide:

Three working days isn't long enough to start gathering the data. If your PSUR is due in six months and half-written in someone's documents folder, a request this week is a problem. The only safe position is to keep your reports and the data behind them current all the time.

How this compares with the EU

The European Commission's December 2025 proposal to amend the EU MDR would make some PSURs less frequent and extend the deadline for less severe serious incidents from 15 to 30 days. That's a proposal, not law. Great Britain has already moved the other way for anticipated serious deterioration, from 30 days to 15.

If you sell in both, the two rulebooks may drift further apart. Many teams now keep one set of surveillance data and produce separate reports for each market. Our guide to PSURs and PMS reports under the EU MDR covers the EU side.

Where MedFortis fits

MedFortis brings together recalls and safety notices from the MHRA, the FDA, Health Canada, Swissmedic, EUDAMED and other national regulators for your devices and similar ones, so your UK team sees corrective actions taken elsewhere as soon as they're published. New signals are assessed by your team and each decision is recorded. The data annex for your PMS report or PSUR can be produced on demand, which helps when the MHRA gives you three working days.

Be ready when the MHRA asks

Book a free 30-minute demo. We'll run MedFortis on your device lines and show you what's been published about them, and what an annex for your next report would contain.

Book a Demo →

Key takeaways

  • New GB post-market surveillance rules apply to devices placed on the market from 16 June 2025.
  • A PMS plan is now mandatory, and incidents with anticipated serious deterioration must be reported within 15 days, down from 30.
  • Proposed field safety notices go to the MHRA first, and you must tell the MHRA about corrective actions abroad even when GB devices aren't affected.
  • The MHRA can ask for your PMS report, PSUR or incident information and expect it within three working days.
This article is provided for general information only and is not legal or regulatory advice. Regulatory requirements are summarised and paraphrased; always refer to the official texts and guidance, and consult a qualified regulatory professional for your specific devices and markets.